Scientific Papers – 2

ERSPC published findings (more )


Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Ballentine Carter H, Veltri RW. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15 (23): 7316-21.

Stephan et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009; 69:198-207.


Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda, MG, Thompson IM, Chan DW.
[-2]Proenzyme prostate specific antigen for prostate cancer detection: A National Cancer Institute Early Detection Research Network validation study. J Urol 2008; 180, 539-543.

Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007.

Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH.
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007.

Contact Information

Monique Roobol
Risk Calculator Administrator

Your Feedback

Tell us what you think about the risk calculators and what your experience has been.

We would welcome your feedback.